Baidu
map

Ann Intern Med:系统性红斑狼疮患者孕产妇和胎儿结局趋势

2019-07-14 xing.T MedSci原创

在这项评估SLE和非SLE妊娠超过18年的大型研究中,院内孕产妇死亡率和总体结局显著改善,尤其是SLE女性。然而,仍需要改善,因为SLE患者的妊娠风险仍然很高。

尽管系统性红斑狼疮(SLE)患者妊娠对孕妇和胎儿都具有高风险,但结局可能正在改善。近日,内科学权威杂志Annals of Internal Medicine上发表了一篇研究文章,该研究旨在评估SLE患者孕产妇和胎儿并发症的全国性趋势和差异。

该研究为1988年至2015年在美国进行的回顾性队列研究,受试者为在国家住院病例(NIS)数据库中有住院治疗记录的有和没有SLE成年孕妇。结局指标包括院内孕产妇死亡率、胎儿死亡率、先兆子痫或子痫、剖腹产、未分娩相关入院和住院时间。为了评估SLE患者与无SLE患者的结局随时间变化的趋势,使用年度和SLE之间的相互作用的Logistic或线性回归(是或否)进行分析。研究人员获得了包含抽样和分层权重的全国人口估计数。

研究人员估计有93820名SLE孕妇和78045054名无SLE患者于1998年至2015年在美国住院治疗。在这18年中,结局有所改善。无症状患者和非SLE患者的院内孕产妇死亡率(每10万人入院率)下降(1998年至2000年为442 vs. 13,2013至2015年为<50 vs. 10),尽管女性SLE患者死亡率下降 (趋势差异,P<0.002)。在所有与妊娠有关的以及与分娩相关的入院中,SLE患者的百分比显著增加。

在这项评估SLE和非SLE妊娠超过18年的大型研究中,院内孕产妇死亡率和总体结局显著改善,尤其是SLE女性。然而,仍需要改善,因为SLE患者的妊娠风险仍然很高。 

原始出处:

Bella Mehta, MBBS,et al.Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis.AIM.2019.https://annals.org/aim/article-abstract/2737824/trends-maternal-fetal-outcomes-among-pregnant-women-systemic-lupus-erythematosus

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2017164, encodeId=e20d201e16412, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Wed Apr 29 22:24:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387355, encodeId=9b8a138e3550d, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Tue Jul 16 09:24:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436225, encodeId=dc3014362250c, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jul 16 09:24:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609862, encodeId=4fcb1609862e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 16 09:24:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2017164, encodeId=e20d201e16412, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Wed Apr 29 22:24:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387355, encodeId=9b8a138e3550d, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Tue Jul 16 09:24:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436225, encodeId=dc3014362250c, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jul 16 09:24:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609862, encodeId=4fcb1609862e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 16 09:24:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2017164, encodeId=e20d201e16412, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Wed Apr 29 22:24:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387355, encodeId=9b8a138e3550d, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Tue Jul 16 09:24:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436225, encodeId=dc3014362250c, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jul 16 09:24:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609862, encodeId=4fcb1609862e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 16 09:24:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2017164, encodeId=e20d201e16412, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Wed Apr 29 22:24:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387355, encodeId=9b8a138e3550d, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Tue Jul 16 09:24:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436225, encodeId=dc3014362250c, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jul 16 09:24:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609862, encodeId=4fcb1609862e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 16 09:24:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]

相关资讯

J Rheumatol:SLE和狼疮性肾炎患者的中性粒细胞胞外陷阱(NETs)

在血管炎(SVV)中,中性粒细胞胞外陷阱(NETs)将修饰的抗原暴露于自身抗体。关于系统性红斑狼疮(SLE)的NETs水平和去除途径知之甚少,尤其是狼疮性肾炎(LN)。这项研究在大型偶发性SLE患者亚组中确定了NETs循环水平并定义了去除率,其中部分患者为新发肾炎。测定了216例偶发性SLE患者(其中103例有偶发性LN)、50例原发性肾小球肾炎患者和健康对照的血清NETs水平(ELISA)、DN

Arthritis Rheumatol:SLE患者直系亲属血浆微生物易位、微生物组与出现自身抗体的关联

这些结果表明血浆微生物易位和微生物组成可能在影响SLE自身抗体产生中起作用。

J Rheumatol:系统性红斑狼疮的血压变异性和年龄相关血压模式

SLE中的年龄相关血压模式与一般人群不同。

J Rheumatol:儿童期虐待与成年患系统性红斑狼疮的关联

与未受到虐待的女性相比,儿童期受到身体和情感虐待的女性患SLE风险明显升高。儿童期遭遇不幸有助于SLE的发展。

J Rheumatol:系统性红斑狼疮中的动脉粥样硬化血管事件

由于对经典冠脉危险因素和SLE的有效治疗,现代SLE的AVE发病率有明显下降。

J Rheumatol:系统性红斑狼疮的疲劳指标

VAS、FSS和FACIT-疲劳量表是2008年至2017年成人SLE研究中最常用的工具。

Baidu
map
Baidu
map
Baidu
map